GW Pharma had a US$2.9 billion market cap on the back of their phase 2 trials of CBD based drug, Epidiolex. Keep in mind Epidiolex was treating an orphan epilepsy condition so the market size was also constrained.
They were US$3.3 billion on completion of phase 3 trials and importantly still pre revenue.
Revenue ramped up dramatically in 2020 and we all know the outcome. Takeover in 2021 for US$7.4 billion by Jazz Pharma.
IMO, do not underestimate the value that IHL will create in the next 2 to 12 months, particularly with 5 clinical trials underway and each addressing a billion dollar market opportunity. OSA is clearly the flagship but each is a company marker.
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-11863
-
-
- There are more pages in this discussion • 8,551 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)